August 1996

Yunnan Lüye Biopharmaceutical Co., Ltd. has been established, focusing on the agency sales and hospital distribution of pharmaceuticals and medical devices across multiple disciplines.

June 1999

Yunnan Longhai Natural Plant Pharmaceutical Co., Ltd. has been established, with multiple production lines including chemical synthesis and small-volume injections.

November 2002

Obtained the drug registration certificate of Fantengzhi injection.

August 2008

The Runhai Beijing Marketing Center has been established, further boosting the vitality and momentum of our nationwide marketing team.

December 2009

Obtained the registration approval of ambroxol hydrochloride injection.

December 2012

Obtained the registration approval for L-carnitine injection.

March 2014

Yunnan Longhai has obtained the GMP certificate for its P2 workshop for small-volume injections, and its production equipment has reached an advanced domestic standard.

May 2014

Yunnan Haifeng Pharmaceutical Co., Ltd. has been established, and the company’s annual production capacity has expanded to 600 million capsules, 30 million sachets of granules, and 600 million tablets.

July 2014

Establish a Yan Tuo demonstration planting base in Lijiang and take charge of seedling propagation.

July 2015

Yunnan Runhai Medical Group has been established, along with a Medical and Import Center, a Research Institute, and an Education College.

March 2016

Yunnan Longhai has obtained the GMP certificate for the P1 workshop for small-volume injections, and the synthesis workshop has begun production.

September 2016

Establish a demonstration base for economic crops and Chinese medicinal materials in Yuxi.

October 2016

Yunnan Longhai P3 aseptic filling production line obtained GMP.

June 2018

Obtained the registration approval for Changchun Xiting Injection.

July 2018

The Runhai Marketing Center has relocated to Wuhan. With this move, the group now encompasses eight subsidiaries, integrating research, cultivation, production, marketing, and education into a single entity.

August 2019

The raw material registration for L-carnitine injection has been approved following the associated review and approval process.

December 2020

Obtain the drug registration certificate of ambroxol hydrochloride solution for inhalation.

June 2021

Obtain the drug registration certificate of doxofylline injection.

September 2021

Obtain the drug registration certificate of propofol medium / long chain fat emulsion injection.

March 2022

Obtain the drug registration certificate of dexmedetomidine hydrochloride injection.

January 2023

Obtain torasemide injection drug registration certificate.

March 2023

Obtained the drug registration certificate of ketorolac tromethamine injection.

February 2024

Obtain the drug registration certificate of acetylcysteine solution for inhalation.

September 2025

Obtain the drug registration certificate of phenylephrine hydrochloride injection.

October 2025

Obtain the drug registration certificate of etomidate medium / long chain fat emulsion injection.